AstraZeneca’s Profit Climbs on Strong Sales of Cancer Drugs

AstraZeneca Plc’s profit grew more than expected in the first quarter, bolstered by demand for its blockbuster cancer medicines.

Earnings per share rose to $2.58 excluding some items, the British drugmaker said Wednesday, ahead of the $2.55 estimated by analysts.